Login Register
icon_bulk_orderBulk order Acrobiosystems for English
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
GMP IL-15 NEW |Omicron specific antibody Hot |Claudin 18.2 |CD3 |GPCRs
0
There is no goods in the shopping cart !
My Cart
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Flt-3

Flt-3

Brief Information

Name:Tyrosine-protein kinase receptor FLT3
Target Synonym:EC:2.7.10.1,CD135 Antigen,CD135,STK1,Growth Factor Receptor Tyrosine Kinase Type III,Fms-Related Tyrosine Kinase 3,Fetal Liver Kinase 2,Fetal Liver Kinase-2,EC 2.7.10.1,fms-Like Tyrosine Kinase 3,Receptor-type tyrosine-protein kinase FLT3,FLT3,FLT-3,FLK2,STK-1,FL cytokine receptor,Fms Related Tyrosine Kinase 3,Stem Cell Tyrosine Kinase 1,FLK-2,Fms Related Receptor Tyrosine Kinase 3,EC 2.7.10
Number of Launched Drugs:11
Number of Drugs in Clinical Trials:37
Lastest Research Phase:Approved

Product ListCompare or Buy

Product> Filter Results
By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
FL3-HF255 Human FITC-Labeled Human Flt-3 / Flk-2 Protein, Fc Tag
FL3-HF255-structure
FL3-HF255-sds
FL3-HF255-elisa_1
FL3-H82E3 Human Biotinylated Human Flt-3 / Flk-2 Protein, His,Avitag™ (MALS verified)
FL3-H82E3-structure
FL3-H82E3-sds
FL3-H82E3-elisa_1
FL3-H52H6 Human Human Flt-3 / Flk-2 Protein, His Tag (MALS verified)
FL3-H52H6-structure
FL3-H52H6-sds
FL3-H52H6-elisa_1
FL3-M52H6 Mouse Mouse Flt-3 / Flk-2 Protein, His Tag
FL3-M52H6-structure
FL3-M52H6-sds
FL3-H5258 Human Human Flt-3 / Flk-2 Protein, Fc Tag (MALS verified)
FL3-H5258-structure
FL3-H5258-sds
FL3-H5258-elisa_1

Part of Bioactivity data

FL3-H82E3-ELISA
Biotinylated Human Flt-3, His,AvitagBiotinylated Human Flt-3, His,Avitag (Cat. No. FL3-H82E3) ELISA bioactivity

Immobilized Human Flt-3 Ligand, His Tag (Cat. No. FLL-H5223) at 1 μg/mL (100 μL/well) can bind Biotinylated Human Flt-3, His,Avitag (Cat. No. FL3-H82E3) with a linear range of 0.039-1.25 μg/mL (QC tested).

Protocol
FL3-H82E3-MALS-HPLC
Biotinylated Human Flt-3, His,Avitag (Cat. No. ) MALS images

The purity of Biotinylated Human Flt-3, His,Avitag (Cat. No. FL3-H82E3) is more than 90% and the molecular weight of this protein is around 97-119 kDa verified by SEC-MALS.

Report
Bioactivity-ELISA
Biotinylated Human Flt-3, His,AvitagBiotinylated Human Flt-3, His,Avitag (Cat. No. FL3-H82E3) ELISA bioactivity

Immobilized Human Flt-3 Ligand, His Tag (Cat. No. FLL-H5223) at 1 μg/mL (100 μL/well) can bind Biotinylated Human Flt-3, His,Avitag (Cat. No. FL3-H82E3) with a linear range of 0.039-1.25 μg/mL (QC tested).

Synonym Name

Flt-3,Flk-2,STK-1,CD135,FLK2,FLT-3

Background

Flt-3(Receptor-type tyrosine-protein kinase FLT3) is also known as FLK-2(Fetal liver kinase-2), STK-1(Stem cell tyrosine kinase 1), CD135. FLT3 is a cytokine receptor which belongs to the receptor tyrosine kinase class III. Tyrosine-protein kinase that acts as cell-surface receptor for the cytokine FLT3LG and regulates differentiation, proliferation and survival of hematopoietic progenitor cells and of dendritic cells. Promotes phosphorylation of SHC1 and AKT1, and activation of the downstream effector MTOR. Promotes activation of RAS signaling and phosphorylation of downstream kinases, including MAPK1/ERK2 and/or MAPK3/ERK1. Mutations that cause constitutive kinase activity promote cell proliferation and resistance to apoptosis via the activation of multiple signaling pathways.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Midostaurin PKC-412; PKC-412A; CGP-41231; CGP-41251 Approved Novartis Pharma Ag Rydapt EU Leukemia, Myeloid, Acute; Mastocytosis Novartis Europharm Ltd 2017-04-28 Leukemia; Hematologic Neoplasms; Mastocytosis, Systemic; Leukemia, Mast-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Hepatic Insufficiency; Leukemia, Myeloid, Acute; Mastocytosis Details
Pexidartinib PLX-3397 Approved Daiichi Sankyo Co Ltd Turalio United States Giant Cell Tumor of Tendon Sheath Daiichi Sankyo Inc 2019-08-02 Giant Cell Tumor of Tendon Sheath; Solid tumours; Synovitis, Pigmented Villonodular; Hodgkin Disease; Arthritis, Rheumatoid; Glioblastoma; Giant Cell Tumors; Prostatic Neoplasms; Gastrointestinal Stromal Tumors; Leukemia, Myeloid, Acute Details
Cabozantinib S-malate XL-184; BMS-907351 Approved Exelixis Inc Cometriq, Cabometyx Japan Carcinoma, Renal Cell Takeda 2012-11-29 Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Pain; Esophageal Neoplasms; Glioblastoma; Kidney Diseases; Prostatic Neoplasms; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Thyroid Neoplasms; Carcinoma, Neuroendocrine; Lymphoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Quizartinib AC-220; ASP-2689; AC-010220 Approved Ambit Biosciences Vanflyta Japan Leukemia, Myeloid, Acute Daiichi Sankyo Co Ltd 2019-06-18 Solid tumours; Leukemia; Myelodysplastic Syndromes; Myeloproliferative Disorders; Hepatic Insufficiency; Leukemia, Myeloid, Acute Details
Ponatinib Hydrochloride AP-24534; INCB-84344; AP24534 HCl; AP24534-HCL; AP24534 hydrochloride Approved Ariad Iclusig Japan Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive Otsuka Holdings Co Ltd 2012-12-14 Leukemia; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Solid tumours; Hematologic Neoplasms; Blast Crisis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Philadelphia Chromosome; Leukemia, Myeloid, Chronic-Phase; Gastrointestinal Stromal Tumors; Leukemia, Myeloid, Acute; Lymphoma; Leukemia, Biphenotypic, Acute Details
Gilteritinib Fumarate ASP-2215 hemifumarate; ASP-2215; 66D-92MGC8M (UNII code) Approved Astellas Pharma Inc Xospata Mainland China Leukemia, Myeloid, Acute Astellas Pharmaceutical (China) Co Ltd 2018-09-21 Solid tumours; Renal Insufficiency; Hepatic Insufficiency; Leukemia, Myeloid, Acute Details
Fedratinib TG-101348; SAR-302503 Approved Sanofi Inrebic EU Splenomegaly; Primary Myelofibrosis Bristol-Myers Squibb Company 2019-08-16 Hematologic Neoplasms; Solid tumours; Polycythemia Vera; Kidney Diseases; Primary Myelofibrosis; Hepatic Insufficiency; Splenomegaly; Thrombocythemia, Essential Details
Brigatinib AP-26113 Approved Takeda Pharmaceutical Co Ltd, Ariad Alunbrig Japan Carcinoma, Non-Small-Cell Lung Takeda 2017-04-28 Solid tumours; Carcinoma; Myofibroma; Lymphoma, Large-Cell, Anaplastic; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Nintedanib Esylate BIBF-1120 Approved C.H. Boehringer Sohn Ag & Co. Kg Ofev, Vargatef Mainland China Idiopathic Pulmonary Fibrosis Boehringer Ingelheim International Gmbh 2014-10-15 Ovarian Neoplasms; Solid tumours; Carcinoma, Renal Cell; Scleroderma, Systemic; Idiopathic Pulmonary Fibrosis; Lung Diseases, Interstitial; Pulmonary Fibrosis; Multiple Myeloma; Prostatic Neoplasms; Peritoneal Neoplasms; Hepatic Insufficiency; Genital Neoplasms, Female; Colorectal Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung Details
Sorafenib Tosylate NSC-724772; BAY-43-0006; BAY-43-9006; BAY-54-9085 Approved Onyx Pharmaceuticals Inc 多吉美, Nexavar EU Thyroid Neoplasms Bayer Ag 2005-12-01 Breast Neoplasms; Neoplasm Metastasis; Fasting; Melanoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Thyroid Neoplasms; Hepatitis C; Hepatitis B; Liver Neoplasms; Liver Diseases; Pancreatic Neoplasms; Kidney Diseases; Carcinoma; Carcinoma, Renal Cell; Kidney Neoplasms; Solid tumours; Ovarian Neoplasms; Leukemia, Myelogenous, Chronic, BCR-ABL Positive Details
Sunitinib Malate PHA-290940; SU-010398; SU-11248; GB-102; PNU-290940; SU-011248-L-malate salt; PNU-290940AD; PHA-290940AD Approved Pfizer Pharmaceuticals Ltd (China) Sutent, 索坦 Japan Pancreatic neuroendocrine tumors (pNET) Pfizer Inc 2006-01-26 Breast Neoplasms; Retinal Vein Occlusion; Neoplasm Metastasis; Carcinoma, Non-Small-Cell Lung; Macular Degeneration; Carcinoma, Hepatocellular; Urogenital Neoplasms; Urologic Neoplasms; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Diabetic macular oedema; Prostatic Neoplasms; Kidney Neoplasms; Neuroendocrine Tumors; Urologic Diseases; Kidney Diseases; Pancreatic Neoplasms; Pancreatic neuroendocrine tumors (pNET); Stomach Neoplasms; Carcinoma, Islet Cell; Carcinoma, Renal Cell; Liver Neoplasms; Solid tumours Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
SKI-G-801 G-801; SKI-G-801; G-749 Hydrochloride Phase 1 Clinical Oscotec Leukemia, Myeloid, Acute Details
Flysyn 4G8-SDIEM Phase 2 Clinical Synimmune Leukemia, Myeloid, Acute Details
Fms-like tyrosine kinase 3 ligand (Celldex Therapeutics) CDX-301 Phase 2 Clinical Amgen Inc Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hodgkin Disease; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell Details
Hydroxychloroquine/Sorafenib Phase 1 Clinical Vg Life Sciences Ovarian Neoplasms Details
FN-1501 FN-1501 Phase 2 Clinical China Pharmaceutical University Solid tumours; Leukemia, Myeloid, Acute; Carcinoma, Hepatocellular Details
QBH-196 QBH-196 Phase 1 Clinical Shenyang Pharmaceutical University Solid tumours; Stomach Neoplasms Details
Crenolanib Besylate ARO-002; CP-868596; ARO-002-26; IND-112201; CP-868596-26 Phase 3 Clinical Pfizer Pharmaceuticals Ltd (China) Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Gastrointestinal Stromal Tumors; Leukemia, Myeloid, Acute; Glioma; Carcinoma, Non-Small-Cell Lung Details
Mivavotinib TAK-659; CB-659 Phase 2 Clinical Takeda Pharmaceutical Co Ltd Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Lymphoma; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma Details
GS-3583 GS-3583 Phase 1 Clinical Gilead Sciences Inc Solid tumours Details
HM-43239 Phase 2 Clinical Hanmi Pharmaceutical Co Ltd Leukemia, Myeloid, Acute Details
Anti-FLT3 CAR-T Cell Therapy (PersonGen Biomedicine) TAA05 Phase 2 Clinical Persongen Biotherapeutics (Suzhou) Co Ltd Leukemia, Myeloid, Acute Details
KC1036 KC1036; KC-1036 Phase 1 Clinical Beijing Konruns Pharmaceutical Co Ltd Hematologic Neoplasms; Solid tumours Details
SEL-24 SEL-24; MEN-1703; SEL-24-1; SEL-24-B489; SEL-24 program Phase 2 Clinical Selvita Leukemia, Myeloid, Acute Details
CA-4948 AU-4948; CA-4948 Phase 2 Clinical Aurigene Leukemia, Myeloid; Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin Details
Ningetinib Tosylate CT-053; CT-053-PTSA Phase 2 Clinical Hec Pharm Co Ltd Solid tumours; Intestinal Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Leukemia, Myeloid, Acute; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
CG-806 CG-806; CG-026806 Phase 1 Clinical Crystalgenomics Inc, Aptose Hematologic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell Details
SKLB-1028 SKLB-1028 Phase 3 Clinical Sichuan University, CSPC Pharmaceutical Group Ltd Solid tumours; Leukemia, Promyelocytic, Acute; Leukemia, Myeloid, Acute Details
AMG-553 AMG-553 Phase 1 Clinical Amgen Inc Leukemia, Myeloid, Acute Details
HH-30134 Phase 1 Clinical Solid tumours; Neoplasms Details
FF-10101 FF-10101; FF-10101-01; FF-10101 succinate Phase 2 Clinical Fujifilm Corp Leukemia, Myeloid, Acute Details
Lestaurtinib SP-924; CEP-701; KT-5555; SPM-924; A-154475.0 Phase 3 Clinical Kyowa Hakko Kirin Leukemia, Myeloid; Bone Marrow Neoplasms; Polycythemia Vera; Prostatic Neoplasms; Psoriasis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Thrombocythemia, Essential Details
NMS-03592088 NMS-P088; NMS-03592088 Phase 2 Clinical Nerviano Medical Sciences Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute Details
E-6201 E-6201 Phase 2 Clinical Eisai Co Ltd Solid tumours; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Myeloproliferative Disorders; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Psoriasis; Brain metastases; Leukemia, Myeloid, Acute; Melanoma Details
LM-061 LM-061 Phase 2 Clinical Shanghai Lixin Pharmaceutical Research and Development Co Ltd Congenital Hyperinsulinism; Solid tumours Details
Clifutinib Besylate Phase 2 Clinical Guangdong Dongyangguang Pharmaceutical Co Ltd Leukemia, Myeloid, Acute Details
ETH-155008 ETH-155008 Phase 1 Clinical Yunnan Shengke Pharmaceutical Co Ltd Leukemia; Leukemia, Promyelocytic, Acute; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute Details
Zotiraciclib TG-02; SB-1317 Phase 2 Clinical Syncore Biotechnology Co Ltd Glioblastoma; Myeloproliferative Disorders; Blast Crisis; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Brain Neoplasms; Gliosarcoma; Astrocytoma; Glioma; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Hepatocellular Details
Flonoltinib maleate Phase 1 Clinical Chengdu Zenitar Biomedical Technology Co Ltd Myeloproliferative Disorders Details
AMG-427 AMG-427 Phase 1 Clinical Amgen Inc Leukemia, Myeloid, Acute Details
RIVAL-01 TBio-6517; TAK-605 Phase 2 Clinical Takeda Pharmaceutical Co Ltd, Turnstone Biologics Solid tumours; Triple Negative Breast Neoplasms; Colorectal Neoplasms Details
MRX-2843 MRX-2843; UNC-2025; UNC-2371 Phase 1 Clinical Meryx, University Of North Carolina At Chapel Hill, University Of Colorado At Denver Leukemia; Solid tumours; Pathologic Processes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Neoplastic Processes; Neoplasm Metastasis Details
Famitinib Malate SHR-1020 Phase 3 Clinical Jiangsu Hengrui Medicine Co Ltd Colorectal Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Fallopian Tube Neoplasms; Urogenital Neoplasms; Endometrial Neoplasms; Lung Neoplasms; Peritoneal Neoplasms; Urologic Neoplasms; Genital Neoplasms, Female; Gastrointestinal Stromal Tumors; Ovarian Neoplasms; Breast Neoplasms; Cholangiocarcinoma; Osteosarcoma; Nasopharyngeal Carcinoma; Idiopathic Pulmonary Fibrosis; Nasopharyngeal Neoplasms; Carcinoma, Transitional Cell; Pancreatic neuroendocrine tumors (pNET); Carcinoma, Renal Cell; Biliary Tract Neoplasms; Solid tumours Details
MG-D-1609 MG-D-1609 Phase 2 Clinical Metagone Biotech Solid tumours Details
Sorafenib/MG-005 MGD-1509; MG-D-1509 Phase 1 Clinical Metagone Biotech, Tri-Service General Hospital Solid tumours Details
XY0206 XY-0206 Phase 1 Clinical Shijiazhuang Yiling Pharmaceutical Co Ltd, Nanjing University Of Chinese Medicine Solid tumours; Leukemia, Myeloid, Acute Details
MAX-40279 Max-40279; MAX-40279-01; MAX-4; MAX-40279-001 Phase 2 Clinical Guangzhou Maxinovel Pharmaceiticals Co Ltd Leukemia; Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Myelodysplastic Syndromes; Colorectal Neoplasms; Leukemia, Myeloid, Acute Details
HYML-122 HYML-122; CHMFL-FLT3-122 Phase 2 Clinical Hefei Academy Of Physical Sciences, Chinese Academy Of Sciences, Hefei Cosource Pharmaceuticals Leukemia, Myeloid, Acute Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
中文网站|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap